{"disease":{"id":"myasthenic-syndromes-congenital","name":"myasthenic syndromes congenital"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06630650","title":"A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT01765140","title":"Treatment Use of 3,4-Diaminopyridine","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Vern C. Juel, M.D.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}